BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease. (Q64139508)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease. |
clinical trial |
Statements
A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease. (English)
0 references
11 August 2016
0 references
20 September 2019
0 references
585
0 references
55 year
0 references